Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program

Why did Netflix's stock drop after Q2 earnings? What impact will Trump's $9B funding cuts have? How are EU sanctions affecting Russian oil prices? Why is Amazon cutting AWS jobs amid AI growth? What caused Taiwan Semiconductor's record profit surge? How will new US crypto laws affect the market? Why is Uber investing heavily in robotaxi partnerships?

Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program

finance.yahoo.com/news/organon-co-ogn-announces-discontinuation-151356254.html

In This Article:
Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational…

This story appeared on finance.yahoo.com, 2025-07-10 15:13:56.